open access

Vol 24, No 1 (2020)
REVIEW
Published online: 2020-03-16
Get Citation

Current guidelines and controversies in the diagnosis and therapy of hypertension in the elderly and very elderly — a review of international recommendations

Piotr Zieleniewicz12, Tomasz Zdrojewski1
·
Arterial Hypertension 2020;24(1):1-9.
Affiliations
  1. Department of Preventive Medicine and Education, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
  2. Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdansk, Poland

open access

Vol 24, No 1 (2020)
REVIEW
Published online: 2020-03-16

Abstract

According to the World Health Organization (WHO) arterial hypertension remains the most important cause of death in the world. Due to ageing of the population and the proven importance of high blood pressure in older age, various expert groups dealing with hypertension worldwide have dedicated more and more separate recommendations to elderly (65–79 years of age) and very elderly patients ( > 80 years of age). The subject of this work is to present and compare current guidelines for the diagnosis and treatment of hypertension developed for this demographic segment. Due to the global significance in shaping the views on hypertension, the following Englishlanguage guidelines have been used for comparative analyses in this work: 2017 ACC/AHA Guideline, 2018 ESC//ESH Guidelines, Hypertension Canada’s 2018 Guidelines, 2019 Hypertension in adults: diagnosis and management by National Institute for Health and Care Excellence (NICE), 2016 Guideline for the diagnosis and management of hypertension in adults by National Heart Foundation of Australia. The comparisons have been made based on of blood pressure criteria, the threshold values for drug treatment initiation and the blood pressure target values.

In summary, hypertension guidelines for the elderly and very elderly differ significantly, although similar trends in their recommendations are evident.

Abstract

According to the World Health Organization (WHO) arterial hypertension remains the most important cause of death in the world. Due to ageing of the population and the proven importance of high blood pressure in older age, various expert groups dealing with hypertension worldwide have dedicated more and more separate recommendations to elderly (65–79 years of age) and very elderly patients ( > 80 years of age). The subject of this work is to present and compare current guidelines for the diagnosis and treatment of hypertension developed for this demographic segment. Due to the global significance in shaping the views on hypertension, the following Englishlanguage guidelines have been used for comparative analyses in this work: 2017 ACC/AHA Guideline, 2018 ESC//ESH Guidelines, Hypertension Canada’s 2018 Guidelines, 2019 Hypertension in adults: diagnosis and management by National Institute for Health and Care Excellence (NICE), 2016 Guideline for the diagnosis and management of hypertension in adults by National Heart Foundation of Australia. The comparisons have been made based on of blood pressure criteria, the threshold values for drug treatment initiation and the blood pressure target values.

In summary, hypertension guidelines for the elderly and very elderly differ significantly, although similar trends in their recommendations are evident.

Get Citation

Keywords

hypertension; blood pressure; systolic pressure; diastolic pressure; aged; aged, 80 and over; practice guideline

About this article
Title

Current guidelines and controversies in the diagnosis and therapy of hypertension in the elderly and very elderly — a review of international recommendations

Journal

Arterial Hypertension

Issue

Vol 24, No 1 (2020)

Pages

1-9

Published online

2020-03-16

Page views

838

Article views/downloads

975

DOI

10.5603/AH.a2020.0004

Bibliographic record

Arterial Hypertension 2020;24(1):1-9.

Keywords

hypertension
blood pressure
systolic pressure
diastolic pressure
aged
aged
80 and over
practice guideline

Authors

Piotr Zieleniewicz
Tomasz Zdrojewski

References (44)
  1. Forouzanfar MH, Afshin A, Alexander LT, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053): 1659–724.
  2. Główny Urząd Statystyczny / Obszary tematyczne / Ludność / Ludność / Struktura ludności. https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc/ludnosc-w-wieku-60-struktura-demograficzna-i-zdrowie,24,1.html (2018 Aug 19).
  3. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000; 355(9207): 865–872.
  4. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens. 2010; 28(7): 1366–1372.
  5. Beckett N, Peters R, Fletcher A, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Eng J Med. 2008; 358(18): 1887–1898.
  6. Veith I. The Yellow Emperor’s classic of internal medicine. Chapters 1–34. University of California Press, Berkeley 2002: 260.
  7. Hippocrates. The Genuine Works of Hippocrates. W Wood, New York 1886: 493.
  8. Galen G. Claudii Galeni Pergameni Introductio in Pulsus Ad Teuthram. Latin Edit. Forgotten Books, London 2018: 96.
  9. Riva-Rocci S. Un nuovo sfigmomanometro. Gazz medica, Torino 1896: 1001–1017.
  10. Korotkoff NSA. contribution to the problem of methods for the determination of blood pressure Rep. Imp Mil Med Acad (St Petersburg). 1905; 11: 365–367.
  11. Hay J. A British Medical Association Lecture on the significance of a raised blood pressure. Br Med J. 1931; 2(3679): 43–47.
  12. Dudley White P. Heart disease. 2nd ed. The Macmillan Company, New York 1937.
  13. Friedberg CK. Diseases of the Heart. Saunders, Philadelphia 1949: 1081.
  14. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980; 140(10): 1280–1285.
  15. Staessen J, Bulpitt C, Clement D, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ. 1989; 298(6687): 1552–1556.
  16. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24): 3255–3264.
  17. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350(9080): 757–764.
  18. Beckett N, Peters R, Fletcher A, et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008; 358(18): 1887–1898.
  19. Antikainen RL, Kastarinen MJ, Jousilahti P, et al. Despite evidence-based guidelines, systolic blood pressure remains inadequately controlled in older hypertensive adults. J Hum Hypertens. 2010; 24(7): 439–446.
  20. Guessous I, Bochud M, Theler JM, et al. 1999-2009 Trends in prevalence, unawareness, treatment and control of hypertension in Geneva, Switzerland. PLoS One. 2012; 7(6): e39877.
  21. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013; 3(8): e003423.
  22. Leenen FHH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ. 2008; 178(11): 1441–1449.
  23. Neuhauser HK, Adler C, Rosario AS, et al. Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008–11. J Hum Hypertens. 2015; 29(4): 247–253.
  24. Zdrojewski Ł, Rutkowski M, Bandosz P, et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381–392.
  25. Falaschetti E, Chaudhury M, Mindell J, et al. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 2009; 53(3): 480–486.
  26. De Macedo ME, Lima MJ, Silva AO, et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens. 2005; 23(9): 1661–1666.
  27. Psaltopoulou T, Orfanos P, Naska A, et al. Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study. Int J Epidemiol. 2004; 33(6): 1345–1352.
  28. Yoon SS, Gu Q, Nwankwo T, et al. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension. 2015; 65(1): 54–61.
  29. McDonald M, Hertz RP, Unger AN, et al. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci. 2009; 64(2): 256–263.
  30. Jacobs JM, Stessman J, Ein-Mor E, et al. Hypertension and 5-year mortality among 85-year-olds: the Jerusalem Longitudinal Study. J Am Med Dir Assoc. 2012; 13(8): 759.e1–759.e6.
  31. Kąkol M, Zdrojewski T, Kąkol-Kozicka K. Rozpowszechnienie, świadomość oraz skuteczność leczenia nadciśnienia tętniczego u ludzi starszych w Polsce ocena metodą sondażu reprezentatywnego. Gerontol Pol. 1999; 7: 23–9.
  32. Broda G, Piotrowski W, Bandosz P. et al. Badanie WOBASZ Senior — ocena epidemiologii czynników ryzyka chorób serca i naczyń u starszych Polaków. . In: Kopeć G, Jankowski P, Pająk A. et al. ed. Epidemiologia i prewencja chorób układu krążenia. 1st ed. Medycyna Praktyczna, Kraków 2015: 93–99.
  33. Zdrojewski T, Wizner B, Więcek A, et al. Prevalence, awareness, and control of hypertension in elderly and very elderly in Poland: results of a cross-sectional representative survey. J Hypertens. 2016; 34(3): 532–8; discussion 538.
  34. Kalarus Z, Balsam P, Bandosz P, et al. NOninvasive Monitoring for Early Detection of Atrial Fibrillation: rationale and design of the NOMED-AF study. Kardiol Pol. 2018; 76(10): 1482–1485.
  35. Cappuccio FP, Markandu ND, Carney C, et al. Double-blind randomised trial of modest salt restriction in older people. Lancet. 1997; 350(9081): 850–854.
  36. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103–2116.
  37. Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1575–1585.
  38. Whelton P, Carey R, Aronow W, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018; 71(19): e127–e248.
  39. Williams B, Mancia G, Spiering W, et al. ESC Scientific Document Group . 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  40. Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018; 34(5): 506–25.
  41. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE Guidelines 2019. https://www.nice.org.uk/guidance/ng136.
  42. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults — 2016. National Heart Foundation of Australia, Melbourne 2016: 84.
  43. Brunström M, Carlberg Bo. Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018; 178(1): 28–36.
  44. Lonn EM, Bosch J, López-Jaramillo P, et al. HOPE-3 Investigators. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016; 374(21): 2009–2020.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl